A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company’s pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Financial Summary
| Share Statistics | NXTS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.8 | $4,059.5 | 1% |
|
| Shares Out (Mil) | 0.8 | 92.2 | 4% |
|
| Institutional Ownership | 22.8% | 82.8% | 10% |
|
| Float (Mil) | 1.1 | 116.0 | 3% |
|
| Beta | 1.86 | 0.78 | 90% |
|
| Avg Daily Volume (000s) | 25 | 151 | 22% |
|
| Price Change (52-week) |
(96.4%) | 85.4% | 2% |
|
| Growth | NXTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 4.0% | na |
|
| Net Income (5yr) | (20.1%) | (0.2%) | 20% |
|
| EPS (5yr) | na | 1.5% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.3%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NXTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $4,298 | na |
|
| Net Income (TTM) (Mil) | ($16) | $58 | 26% |
|
| EPS (TTM) | ($33.584) | $0.300 | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | $446 | 25% |
|
| Net Cash Flow (TTM) (Mil) | $5 | $4 | 52% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $1,795 | 12% |
|
| Enterprise Value (Q1) (Mil) | ($6) | $5,650 | 2% |
|
| Valuation | NXTS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.46 | 1.59 | 37% |
|
| P/E | na | 24.0 | na |
|
| Dividend Yield | na | 1.2% | na |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | NXTS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 27.5% | na |
|
| Net Margin | na | 3.0% | na |
|
| ROA | (121.2%) | 1.5% | 5% |
|
| ROE | (417.9%) | 3.9% | 2% |
|
| Liabilities to Assets | 90.5% | 54.0% | 87% |
|
| F-Score | 3 | 5 | 18% |
|
Nexentis Technologies Inc. did not pass any screens on 8/27/2026.
